Usability of mepolizumab single-use prefilled autoinjector for patient self-administration

References

• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012;42:650–8. doi:10.1111/j.1365-2222.2011.03929.x.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Mepolizumab (NUCALA) US prescribing information. 2015 [accessed 2018 Dec 4]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125526s004lbl.pdf.
   Google Scholar
• GlaxoSmithKline UK. Mepolizumab (NUCALA) EU summary of product characteristics [accessed 2018 Dec 4]. https://www.ema.europa.eu/documents/product-information/nucala-epar-product-information_en.pdf.
   Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–9. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, for the SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–97. doi:10.1056/NEJMoa1403291.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400. doi:10.1016/S2213-2600(17)30125-X.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Cohen S, Dowd JE, Edwards W, Thakker S, Wellborne FR, Renz CL, Segurado OG. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28:1619–29. doi:10.1016/j.clinthera.2006.10.006.
   PubMed Web of Science ®Google Scholar
• Noone J, Blanchette CM. The value of self-medication: summary of existing evidence. J Med Econ. 2018;21:201–11. doi:10.1080/13696998.2017.1390473.
   PubMed Web of Science ®Google Scholar
• Shabbir S, Pouliquen I, Bentley JH, Bradford ES, Kaisermann MC, Albayaty M. The pharmacokinetics and relative bioavailability of mepolizumab 100 mg liquid formulation administered subcutaneously to healthy participants: a randomized trial. American Thoracic Society International Conference; 2019 May; Dallas, TX, USA.
   Google Scholar
• Bel EH, Bernstein DI, Bjermer L, Follows R, Bentley JH, Pouliquen I, Bradford E. Usability of mepolizumab single-use prefilled syringe for patient self-administration. J Asthma. 2019:24:1–10. doi:10.1080/02770903.2019.1604745.
   Google Scholar
• Huynh TK, Ostergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93–9. doi:10.2147/PPA.S55156.
   PubMed Web of Science ®Google Scholar
• Keininger D, Coteur G. Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life Outcomes. 2011;9:2. doi:10.1186/1477-7525-9-2.
   PubMed Web of Science ®Google Scholar
• Sheikh SZ, Hammer AE, Fox NL, Groark J, Struemper H, Roth D, Gordon D. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus. Int J Clin Pharmacol Ther. 2016;54:914–22. doi:10.5414/CP202623.
   PubMed Web of Science ®Google Scholar
• Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, Gardulf A, Eichmann F, Haag S, Massion C, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65–72. doi:10.1007/s10875-006-8905-x.
   PubMed Web of Science ®Google Scholar
• Tjalma W, Huizing MT, Papadimitriou K. The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home. Facts Views Vis Obgyn. 2017;9:51–5.
   PubMed Web of Science ®Google Scholar
• Hupperts R, Becker V, Friedrich J, Gobbi C, Salgado AV, Sperling B, You X. Multiple sclerosis patients treated with intramuscular IFN-beta-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv. 2015;12:15–25. doi:10.1517/17425247.2015.989209.
   PubMed Web of Science ®Google Scholar
• Freundlich B, Kivitz A, Jaffe JS. Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations. J Clin Rheumatol. 2014;20:256–60. doi:10.1097/RHU.0000000000000117.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach F, Dao Trong M, Grange L, Laurent PE, Abry H, Cotten J, Granger C. Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis. Patient Prefer Adherence. 2014;8:199–209. doi:10.2147/PPA.S50583.
   PubMed Web of Science ®Google Scholar
• Lange J, Richard P, Bradley N. Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population. Med Devices (Auckl). 2015;8:255–64. doi:10.2147/MDER.S85938.
   PubMedGoogle Scholar